EGFR Mutations in Lung Cancer: Types, Testing, and Treatment Implications

Clinical Significance

EGFR (epidermal growth factor receptor) mutations are the most common actionable driver in non-small cell lung cancer (NSCLC), especially adenocarcinoma. Prevalence: ~15% Western, 35–50% Asian; higher in never-smokers, women. Predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs).

Major Mutation Classes

ClassExamplesFrequencyTKI Sensitivity
Classical (sensitizing)Exon 19 deletion (del19), L858R (exon 21)~85–90% of EGFR+High (1st/2nd/3rd gen)
Exon 20 insertionsA767_V769dup, D770_N771insSVD, etc.~4–10%Resistant to 1st/2nd/3rd gen; sensitive to exon 20-specific (amivantamab, mobocertinib, CLN-081)
Resistance (acquired)T790M (exon 20), C797S, L718Q, G724S, etc.Post-TKI progressionT790M → osimertinib (3rd gen); C797S cis/trans → combo strategies
Uncommon sensitizingG719X (exon 18), L861Q (exon 21), S768I (exon 20)~5–10%Variable; often respond to afatinib/osimertinib

Testing Standards

  • Method: NGS panel (tissue or liquid biopsy/ctDNA) – detects all classes + co-mutations (TP53, MET amp, PIK3CA).
  • Timing: At diagnosis (advanced NSCLC adenocarcinoma); at progression on TKI (resistance mechanism).
  • Liquid biopsy: Non-invasive; detects resistance earlier; tissue if negative/insufficient.

Treatment Algorithm (2024)

  1. 1st line (classical): Osimertinib (preferred; FLAURA OS benefit, CNS activity). Alternatives: afatinib, dacomitinib, gefitinib, erlotinib.
  2. 1st line (exon 20 ins): Amivantamab + chemo (PAPILLON) or mobocertinib (accelerated approval withdrawn US; available elsewhere).
  3. Progression on 1st/2nd gen: Test for T790M → osimertinib if +; else chemo ± bevacizumab.
  4. Progression on osimertinib: Biopsy/ctDNA for resistance mechanism → clinical trial (4th gen TKIs, combos) or chemo ± anti-angiogenic.
  5. Brain mets: Osimertinib penetrates BBB; local therapy (SRS) for symptomatic/oligoprogressive.

Key Co-Mutations Impacting Outcome

  • TP53 co-mutation → shorter PFS, higher transformation risk.
  • MET amplification → bypass resistance; capmatinib + osimertinib trials.
  • RB1/PTEN loss → small cell transformation.

Emerging Horizons

  • 4th-gen TKIs (BLU-945, BBT-207) targeting C797S.
  • Antibody-drug conjugates (patritumab deruxtecan).
  • Bispecifics (amivantamab).
  • Neoadjuvant/adjuvant osimertinib (ADAURA – DFS benefit in stage IB–IIIA).

Bottom Line

EGFR testing is mandatory in non-squamous NSCLC. Mutation subclass determines first-line therapy. Serial monitoring (ctDNA) guides resistance management. Clinical trials offer next-line options.

Genetic Disorders - Related Articles